Mobility claims for dog foods Anton C. Beynen Vobra Special - - PowerPoint PPT Presentation

mobility claims for dog foods
SMART_READER_LITE
LIVE PREVIEW

Mobility claims for dog foods Anton C. Beynen Vobra Special - - PowerPoint PPT Presentation

Mobility claims for dog foods Anton C. Beynen Vobra Special Petfoods, Veghel, The Netherlands Functional foods: mobility dog foods Health claim Therapeutic claim Substances used for canine mobility support Fish oil Undenaturated


slide-1
SLIDE 1

Mobility claims for dog foods

Anton C. Beynen Vobra Special Petfoods, Veghel, The Netherlands

slide-2
SLIDE 2

Functional foods: mobility dog foods

  • Health claim
  • Therapeutic claim
slide-3
SLIDE 3

Substances used for canine mobility support

  • Fish oil
  • Gelatin hydrolysate
  • Beta-1,3/1,6-glucans
  • Glucosamine
  • Chondroitin sulfate
  • Green-lipped mussel
  • Boswellia resin
  • Mulberry extract
  • Elk velvet antler
  • Undenaturated type-II

collagen

  • Curcumin
  • Milk protein concentrate
  • Methyl sulfonyl methane
  • Devil’s claw
  • Green tea
  • Grape skin
  • Vitamin E
slide-4
SLIDE 4

Functional ingredients used in mobility dog food

  • Fish oil
  • Gelatin hydrolysate
  • Beta-1,3/1,6-glucans
  • Glucosamine
  • Chondroitin sulfate
  • Green-lipped mussel
  • Boswellia resin
  • Mulberry extract
  • Devil’s claw
  • Green tea
  • Grape skin
  • Curcumin
slide-5
SLIDE 5

Clinical signs of osteoarthritis

  • Lameness
  • Stiffness
  • Reduced movement in

joint

  • Reluctance or

difficulty with exercise

  • Crepitus
  • Painful, warm,

swollen joints

  • Muscle atrophy
slide-6
SLIDE 6

Mobility foods with healthy mobility/joint claim

  • Prevention of joint disease has not (yet) been

investigated

  • Claims are backed by research in canine patients
slide-7
SLIDE 7

EU legislation on therapeutic foods for

  • steoarthritis (Regulation 1070/2010)
  • Particular nutritional purpose: supporting joint

metabolism in case of osteoarthritis

  • Therapeutic dog food: minimum contents of 3.3%
  • mega-3 fatty acids and 0.38% EPA in dietary dry

matter

slide-8
SLIDE 8

Placebo effects in trials on canine osteoarthritis

  • Shown in many studies
  • Magnitude of placebo effect can be similar to that
  • f corrected treatment effect
  • Caused by biased evaluation of clinical signs

and/or time effects

  • Non-controlled, open studies are inconclusive
slide-9
SLIDE 9

Effective, functional ingredients in the treatment of canine osteoarthritis

  • Fish oil: weak effect
  • Gelatin hydrolysate: small effect, but

reproducibility unknown

  • Beta-1,3/1,6-glucans: weak effect, but

reproducibility unknown

slide-10
SLIDE 10

Perpetuating cycle of osteoarthritis

Synovitis Cytokines Cartilage degeneration PG MP release

slide-11
SLIDE 11

Basis for dietary treatment of osteoarthritis

  • Reduction of overweight
  • Inhibition of inflammation
  • Preservation of cartilage-matrix
slide-12
SLIDE 12

Glucosamine, chondroitin sulfate, green- lipped mussel and curcumin

  • No evidence for efficacy in the treatment of canine
  • steoarthtritis
  • Data evaluation and literature references are

available on request: beynen@freeler.nl

slide-13
SLIDE 13

Glucosamine and chondroitin sulfate

  • Substrates for proteoglycan synthesis
  • Source: crustacean shells and animal cartilage
  • Absorption efficiency: 11 and 5%
  • Ineffective in 4 out of 5 double-blind, placebo-

controlled trials in osteoarthritic dogs

  • Dose: 25-61 and 22-48 mg/kg body weight
slide-14
SLIDE 14

Green-lipped mussel

  • Powders, oily extracts
  • Active principle unknown
  • Anti-inflammatory action in model systems
  • No or meaningless effect in 5 double-blind,

placebo-controlled trials in osteoarthritic dogs

  • Dose: 53 or 139 mg/MJ metabolizable energy
slide-15
SLIDE 15

Curcumin

  • Curcuminoid derivatives reduce inflammation and

cartilage breakdown in-vitro

  • No effect on lameness in a double-blind, placebo-

controlled trial in osteoarthritic dogs

  • Induction of skin malodor and yellow coloring of

food

slide-16
SLIDE 16

Boswellia resin

  • Active principle: pentacyclic triterpenic

(boswellic) acids

  • In-vitro inhibition of inflammation
  • One open, non-controlled trial in osteoarthritic

dogs

slide-17
SLIDE 17

Devil’s claw

  • Active principle: harpagoside
  • In-vitro inhibition of inflammation
  • Anecdotical efficacy in dogs with osteoarthritis
slide-18
SLIDE 18

Green tea

  • Active principle: epigallocacetchin gallate

(EGCG)

  • In-vitro antioxidant activity and inhibition of

inflammation

  • Study in mice with collagen-induced arthritis
slide-19
SLIDE 19

Grape skin extract

  • Active principle: resveratrol
  • In-vitro antioxidant activity and inhibition of

inflammation

  • Studies in rabbits with LPS-induced arthritis and

mice with carrageenan-induced arthritis

slide-20
SLIDE 20

Fish oil and canine osteoarthritis

  • Active principle: EPA
  • Anti-inflammatory effect
  • In-vitro inhibition of cartilage proteoglycan

catabolism

  • Four randomized, double-blind, controlled trials

have assessed changes over time in severity of clinical signs

slide-21
SLIDE 21

Osteoarthritis signs in dogs given fish oil in capsules

  • r diets: improvement effect versus baseline

Authors Placebo Fish oil Effect Roush et al., 2010 0.5 0.9 0.4 Hielm-Björkman et al., 2012 0.2 0.3 0.1 Moreau et al., 2013 1.0 1.8 0.8 Mehler et al., 2016 0.1 4.3 4.2 Changes on a (standardized) 0-10 scale

slide-22
SLIDE 22

Design of clinical trial (Roush et al., 2010)

  • Double-blinded, placebo-controlled trial
  • Client-owned dogs; 16 or 22 per treatment
  • Dry and canned foods without or with 0.4% EPA
  • n a dry matter basis for 90 days
  • Assessment by veterinarians of lameness, weight

bearing, reluctance to hold up contralateral limb and pain on a 1-5 scale

slide-23
SLIDE 23

Improvement versus baseline of clinical

  • steoarthritis after feeding fish oil (Roush et al.

2010)

0.5 1 1.5

Lameness Weight bearing Hold up leg Pain Fish oil Control

Effect of fish oil = 0.4 units

slide-24
SLIDE 24

Gelatin hydrolysate and canine osteoarthritis

  • Source: bone and skin of swine and cattle
  • Supply of substrates for collagen synthesis:

glycine, proline, hydroxyproline

  • Inhibition of matrix metalloproteinase-3 activity
slide-25
SLIDE 25

Design of clinical trial with gelatin hydrolysate (Beynen et al., 2010)

  • Double-blinded, placebo-controlled trial
  • Privately owned dogs; 15 per treatment
  • Identical, dry diet
  • 10 g per day of either gelatin hydrolysate

(Rousselot ASF) or soya protein isolate for 8 weeks

  • Questionnaire (activity, stiffness, lameness, pain
  • n a 0-10 scale)
slide-26
SLIDE 26

Improvement versus baseline of clinical

  • steoarthritis after feeding gelatin hydrolysate

0.5 1 1.5 2

Lameness Stiffness Pain Activity Gelatin Control

Effect of gelatin hydrolysate = 1.3 units

slide-27
SLIDE 27

Effective, functional ingredients in the treatment of canine osteoarthritis

  • Fish oil: weak effect
  • Gelatin hydrolysate: small effect, but

reproducibility unknown

  • Beta-1,3/1,6-glucans: weak effect, but

reproducibility unknown

  • Combination might work synergistically